中国当代医药
中国当代医药杂志欢迎您 今天是   2025年4月3日星期四
设为首页  加入收藏  联系我们         
 
      首 页    |    本刊简介     |    期刊荣誉     |    编采团队     |    会务培训     |    理事单位     |    下载专区     |    在线留言     |    联系我们     |     返回中国当代医药网
中国当代医药  2020, Vol. 27 Issue (33): 43-46    
  临床研究 本期目录 | 过刊浏览 | 高级检索 |
谷胱甘肽联合前列地尔治疗脓毒症急性肾损伤的效果
罗炬辉1 徐 仲2 龙信聪3 龙永健1 胡会连1
1.广州市白云区第二人民医院重症医学科,广东广州 510450;
2.广州医科大学附属第三医院重症医学科,广东广州510150;
3.广州医科大学附属第三医院心内科,广东广州 510150
Effect of Glutathione combined with Alprostadil treating acute kidney injury in sepsis
LUO Ju-hui1 XU-Zhong2▲ LONG Xin-cong3 LONG Yong-jian1 HU Hui-lian1
1.Department of Critical Care Medicine,the Second People′s Hospital of Baiyun District in Guangzhou City,Guangdong Province,Guangzhou 510450,China;
2.Department of Critical Care Medicine,the Third Affiliated Hospital of Guangzhou Medical University,Guangdong Province,Guangzhou 510150,China;3.Department of Cardiology,the Third Affiliated Hospital of Guangzhou Medical University,Guangdong Province,Guangzhou 510150,China
全文: PDF (0 KB)   HTML (36 KB) 
输出: BibTeX | EndNote (RIS)      
摘要 目的 探讨谷胱甘肽联合前列地尔治疗脓毒症急性肾损伤的效果。方法 回顾性分析2017年1月~2019年6月广州市白云区第二人民医院重症医学科收治的80例脓毒症急性肾损伤患者临床资料,按不同药物治疗方式分为联合组和对照组,每组各40例。对照组予以常规静脉滴注前列地尔,10 μg/次,qd;联合组在对照组治疗的基础上加以谷胱甘肽治疗,0.6 g/次,qd,两组均予以治疗10 d。观察两组治疗10 d后的疗效及血清中组织纤溶酶原激活物(TPA)、纤溶酶原激活物抑制物(PAI-1)水平的变化;采用急性生理与慢性健康评分(APACHEⅡ)、全身感染相关性器官功能衰竭评分( SOFA)评估病情变化。结果 联合组治疗总有效率高于对照组,差异有统计学意义(P<0.05);联合组血清TPA、PAI-1 平低于对照组,差异有统计学意义(P<0.05);联合组APACHEⅡ、SOFA评分低于对照组,差异有统计学意义(P<0.05)。结论 谷胱甘肽联合前列地尔在脓毒症急性肾损伤治疗中可提高疗效,降低体内TPA、PAI-1水平。
服务
把本文推荐给朋友
加入我的书架
加入引用管理器
E-mail Alert
RSS
作者相关文章
罗炬辉
徐 仲
龙信聪
龙永健
胡会连
关键词 谷胱甘肽前列地尔脓毒症急性肾损伤组织纤溶酶原激活物纤溶酶原激活物抑制物    
AbstractObjective To explore the effect of Glutathione combined with Alprostadil treating acute kidney injury in sepsis.Methods The clinical data of 80 patients with acute kidney injury in sepsis admitted to the Department of Intensive Medicine of the Second People′s Hospital of Baiyun District,Guangzhou from January 2017 to June 2019 were analyzed retrospectively.According to the different drug treatment methods,they were divided into the combined group and the control group,40 cases in each group.The control group received routine intravenous drip of Alprostadil,10 μg/time,qd;the combined group received glutathione treatment on the basis of the control group,0.6 g/time,qd,both groups were treated for 10 days.The curative effect at 10 days after treatment and the changes in serum tissue plasminogen activator (TPA) and plasminogen activator inhibitor (PAI-1) levels of the two groups were observed;the acute physiology and chronic health scores (APACHE Ⅱ),systemic infection-related organ failure score (SOFA) were used to assess the changes in patients′ condition.Results The total effective rate of the combined group was higher than that of the control group,the difference was statistically significant difference (P<0.05);the serum TPA and PAI-1 levels of the combined group were lower than those of the control group,there were statistically significant differences(P<0.05);the APACHEⅡand SOFA scores of the combined group were lower than those of the control group,the differences were statistically significant (P<0.05).Conclusion Glutathione combined with Alprostadil can improve the therapeutic effect and reduce the levels of TPA and PAI-1 in patients with acute kidney injury in sepsis.
Key wordsGlutathione    Alprostadi    Sepsis    Acute kidney injury    Tissue plasminogen activator    Plasminogen activator inhibitor
    
基金资助:广东省广州市白云区科技计划项目(2018-YL-025)
作者简介: 罗炬辉(1982-),男,汉族,广东广州人,本科,主治医师,研究方向:重症医学
引用本文:   
罗炬辉;徐 仲;龙信聪;龙永健;胡会连. 谷胱甘肽联合前列地尔治疗脓毒症急性肾损伤的效果[J]. 中国当代医药, 2020, 27(33): 43-46.
LUO Ju-hui;XU-Zhong;LONG Xin-cong;LONG Yong-jian;HU Hui-lian. Effect of Glutathione combined with Alprostadil treating acute kidney injury in sepsis. 中国当代医药, 2020, 27(33): 43-46.
链接本文:  
https://www.dangdaiyiyao.com/CN/     或     https://www.dangdaiyiyao.com/CN/Y2020/V27/I33/43
中华人民共和国互联网药品信息服务资格证书(京)-非经营性-2016-0092
京ICP备11001767号-6  京公网安备 11010502046607号  互联网药品信息服务资格证  期刊出版许可证  广告经营许可证
信息产业部备案管理系统网址 http://beian.miit.gov.cn/state/outPortal/loginPortal.action
投稿热线:010-59626690 总机:010-59626692/18/19/20   传真:010-59626204   投稿信箱:ddyy@vip.163.com
地址:北京市朝阳区东四环中路78号楼(大成国际中心B1座)8B02室   邮编:100124
技术支持:北京玛格泰克科技发展有限公司
Copyright 2000-2014 版权所有 《中国当代医药》杂志社 未经授权请勿转载